[go: up one dir, main page]

WO1996039504A3 - Methods for distinguishing metastatic and non-metastatic cancers, polynucleotides and polypeptides for use therein - Google Patents

Methods for distinguishing metastatic and non-metastatic cancers, polynucleotides and polypeptides for use therein Download PDF

Info

Publication number
WO1996039504A3
WO1996039504A3 PCT/EP1996/002461 EP9602461W WO9639504A3 WO 1996039504 A3 WO1996039504 A3 WO 1996039504A3 EP 9602461 W EP9602461 W EP 9602461W WO 9639504 A3 WO9639504 A3 WO 9639504A3
Authority
WO
WIPO (PCT)
Prior art keywords
metastatic
methods
polynucleotides
polypeptides
distinguishing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1996/002461
Other languages
French (fr)
Other versions
WO1996039504A2 (en
Inventor
Emilay Shtivelman
Adam Sampson-Johannes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH Austria
Sandoz AG
Systemix Inc
Original Assignee
Sandoz Erfindungen Verwaltungs GmbH
Sandoz AG
Systemix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Erfindungen Verwaltungs GmbH, Sandoz AG, Systemix Inc filed Critical Sandoz Erfindungen Verwaltungs GmbH
Priority to AU63008/96A priority Critical patent/AU6300896A/en
Publication of WO1996039504A2 publication Critical patent/WO1996039504A2/en
Publication of WO1996039504A3 publication Critical patent/WO1996039504A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57423Specifically defined cancers of lung
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Nucleotide sequences encoding a novel classic small cell lung carcinoma-specific cDNA, the amino acid sequence of the protein, methods for expressing and purifying the protein, antibodies against the protein and methods of use thereof are provided.
PCT/EP1996/002461 1995-06-06 1996-06-06 Methods for distinguishing metastatic and non-metastatic cancers, polynucleotides and polypeptides for use therein Ceased WO1996039504A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU63008/96A AU6300896A (en) 1995-06-06 1996-06-06 Methods for distinguishing metastatic and non-metastatic cancers, polynucleotides and polypeptides for use therein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47172395A 1995-06-06 1995-06-06
US08/471,723 1995-06-06

Publications (2)

Publication Number Publication Date
WO1996039504A2 WO1996039504A2 (en) 1996-12-12
WO1996039504A3 true WO1996039504A3 (en) 1997-01-09

Family

ID=23872750

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/002461 Ceased WO1996039504A2 (en) 1995-06-06 1996-06-06 Methods for distinguishing metastatic and non-metastatic cancers, polynucleotides and polypeptides for use therein

Country Status (2)

Country Link
AU (1) AU6300896A (en)
WO (1) WO1996039504A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4263599A (en) * 1998-05-18 1999-12-06 Isis Innovation Limited Nucleic acid encoding protein, down-regulated in metastasis (drim), and its diagnostic and therapeutic use
WO2005007692A1 (en) * 2003-07-11 2005-01-27 Uab Research Foundation Antibodies that recognize the brms1 protein and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000757A1 (en) * 1990-07-09 1992-01-23 Research Corporation Technologies, Inc. Diagnosis of metastatic cancer by the mts-1 gene
WO1994001777A1 (en) * 1992-07-14 1994-01-20 Michigan Cancer Foundation Method of determining metastatic potential of tumor cells
WO1994020147A1 (en) * 1993-03-04 1994-09-15 Systemix, Inc. Small animal metastasis model

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000757A1 (en) * 1990-07-09 1992-01-23 Research Corporation Technologies, Inc. Diagnosis of metastatic cancer by the mts-1 gene
WO1994001777A1 (en) * 1992-07-14 1994-01-20 Michigan Cancer Foundation Method of determining metastatic potential of tumor cells
WO1994020147A1 (en) * 1993-03-04 1994-09-15 Systemix, Inc. Small animal metastasis model

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
8TH INTERNATIONAL CONGRESS OF IMMUNOLOGY, Budapest, Hungary, August 23-28, 1992 Springer-Verlag Budapest See M.SALMI ET AL.: Expression of domain 3 *
EMBL DATABASE, Accession number T72319 Sequence reference HS31940 from human cDNA clone 85879;17 March 1995 *
EMBL DATABASE, Accession number T96211 Sequence reference HS21168 from human cDNA clone 120965;14 April 1995 *
POLLOCK ET AL.: "Cloning, sequencing, and expression of the gene encoding the high-molecular-weight Cytochrome c from Desulfovibrio vulgaris Hildenborough", JOURNAL OF BACTERIOLOGY, vol. 173, no. 1, January 1991 (1991-01-01), pages 220 - 228, XP000609018 *
S.SEITER ET AL.: "Prevention of tumor metastasis formation by anti-variant CD44", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 177, no. 2, 1 February 1993 (1993-02-01), NEW YORK US, pages 443 - 455, XP002018001 *

Also Published As

Publication number Publication date
WO1996039504A2 (en) 1996-12-12
AU6300896A (en) 1996-12-24

Similar Documents

Publication Publication Date Title
AU7165287A (en) DNA encoding streptavidin, streptavidin produced therefrom, fused polypeptides which include amino acid sequences present in streptavidin and uses thereof
CA2263889A1 (en) P-selectin ligand proteins
SI0917571T1 (en) Agouti-related gene
WO2000008057A3 (en) Molecules designated b7l-1
HU9601448D0 (en) Novel apoptosis-modulating proteins, dna encoding the proteins and methods of use thereof
IL193886A0 (en) Antibodies that bind to ldcam sequences
WO2000006738A3 (en) NUCLEIC ACIDS AND PROTEINS FROM $i(STREPTOCOCCUS PNEUMONIAE)
WO1998021343A8 (en) Genes encoding telomerase proteins
HUT46061A (en) Dna sequences encoding hirudin-like protein and process for producing such proteins
WO1993018146A3 (en) Proteins forming complexes with chaperones and ligands thereof, fragments thereof, preparation thereof and biological uses thereof
CA2302147A1 (en) Methods for protein screening
CA2336261A1 (en) Cyclin e2 genes and proteins
WO1995030001A3 (en) Novel p-selectin ligand protein
EP1117779A4 (en) $i(MORAXELLA CATARRHALIS) PROTEIN, NUCLEIC ACID SEQUENCE AND USES THEREOF
HUP0300851A3 (en) Purified proteins, recombinant dna sequences and processes for producing caffeine free beverages
AU1239997A (en) Polypeptides corresponding to the amino acid sequences of proteins p57 or p9.5 of Borna disease virus, nucleic acid fragments coding therefore and their use for diagnostic and immunization purposes
WO1996039504A3 (en) Methods for distinguishing metastatic and non-metastatic cancers, polynucleotides and polypeptides for use therein
NZ294019A (en) Proteins associated with the hippocampus; dna sequences coding therefor, antibodies to the proteins
WO2000020450A3 (en) Calcium channel alpha-2/delta gene
EP0970192A4 (en) NUCLEIC ACID ENCODING $i(M. TUBERCULOSIS) ALGU PROTEIN
EP0816498A3 (en) Excitatory amino acid receptor protein and related nucleic acid compounds
WO2001087932A3 (en) Seven transmembrane proteins and polynucleotides encoding the same
CA2311646A1 (en) Tsa305 gene
WO2001049714A3 (en) Nope polypeptides, encoding nucleic acids and methods of use
DE69939587D1 (en) Semaphorin polypeptide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA